期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Clinical and Technological Dependence Characteristics on a Series of Brazilian Cases with Infantile Onset Pompe Disease in Enzyme Replacement Therapy
1
作者 Paula De Almeida Thomazinho Eliana Pelissari +8 位作者 Regina Celia Beltrao Duarte Carolina Fishinger Moura De Souza Heloise Helena Siqueira Borges Maria Da Gloria Cruvinel Horta Liane De Rosso Giuliani Ana Maria Martins Lilian Stewart Dafne Dain Gandelman Horovitz Juan Clinton Llerena 《Open Journal of Clinical Diagnostics》 2019年第1期16-32,共17页
Pompe disease (PD) is a rare inborn error of metabolism due to an abnormal acid alpha-glucosidase (GAA) activity that comprises glycogen breakdown mainly in the lysosomes. Since the introduction of enzyme replacement ... Pompe disease (PD) is a rare inborn error of metabolism due to an abnormal acid alpha-glucosidase (GAA) activity that comprises glycogen breakdown mainly in the lysosomes. Since the introduction of enzyme replacement therapy (ERT), with recombinant human GAA for the early onset PD patient, a relevant field of clinical research due to the benefits regarding survival rate has been widely documented worldwide. Objective: To describe the clinical characteristics and the ERT effects in a series of Brazilian patients with infantile onset PD (IOPD) under ERT. Methods: Brazilian patients diagnosed with IOPD under ERT were recruited through their physicians participating in the International Pompe Disease Registry from 2009 to 2017. Data were collected by an online survey. Results: 10 IOPD patients were identified through the survey with a death rate of 30% and technology dependency rate reported as 80% (motor, respiratory or nutritional fields) of the patients. After the third year of ERT, motor disabilities were lost in 50% of ambulated patients. The overall characteristics were similar to international studies. Conclusion: Despite ERT benefits in cardiac involvement, motor disabilities seem to be much more compromised in IOPD patients, with high technology dependence, especially after three years of age. 展开更多
关键词 Motor Development Child Disability Glycogen Storage Disease Type II Enzyme Replacement Therapy
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部